Description:

ODM derived from http://clinicaltrials.gov/show/NCT00586794

Link:

http://clinicaltrials.gov/show/NCT00586794

Keywords:
Versions (3) ▾
  1. 12/9/13
  2. 4/15/14
  3. 8/11/14
Uploaded on:

August 11, 2014

DOI:
No DOI assigned. To request one pleaselog in.
License:
Creative Commons BY 4.0
Model comments:

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Itemgroup comments for:

Item comments for:

In order to download data models you must be logged in. Please log in or register for free.

Eligibility NCT00586794 Pulmonary Arterial Hypertension (PAH)

Eligibility

  1. StudyEvent: Eligibility
    1. Eligibility
Inclusion Criteria
age at least 14 Years
Written informed consent obtained
No participation in another AMG driven study attendancing this treatment protocol
Presence of cyanosis with < 93 % arterial oxygen saturation (measured by transcutaneous pulse oximetry)
Clinical indication for the invasive diagnostic procedures planned for the study is given. This is evaluated on the basis of observation before, during and after medicinal therapy)
Presence of PAH as diagnosed by invasive methods with Rp:Rs > 0.5 measured at rest, before testing of pulmonary vasodilatory reserve
Diagnosis
non-corrected large congenital shunting defect at atrial, ventricular or arterial level:
Partial anomalous pulmonary venous drainage, Partial Anomalous Pulmonary Venous Return
Atrial Septal Defects
Atrial Septal Defect Sinus Venosus, Sinus venosus atrial septal defect
Ventricular Septal Defects
Atrioventricular septal defect, Atrioventricular septal defect and common atrioventricular junction
TAC
Aortopulmonary window, Aortopulmonary septal defect
Persistent ductus arteriosus, Patent ductus arteriosis
combinations thereof
Surgically corrected shunting defect (diagnoses as above) with significant residual defect
Other diagnoses with univentricular physiology/ hemodynamics.
Exclusion Criteria
pregnancy or lactation
women of child-bearing age who are sexually active without practising highly effective methods of contraception
any diseases or impairment that, in the opinion of the investigator exclude a subject from participation
substance abuse (alcohol, medicines, drugs)
other medical, psychological or social circumstances that would adversely affect a patient's ability to participate reliably in the study or increase the risk to themselves or others if they participated
insufficient compliance
missing willingness to storaging and transferring pseudonymous disease data within this study.
subjects who are not able to perform Cardio-Pulmonary Exercise Testing (CPX).
pulmonary hypertension secondary to any etiology other than those specified in the inclusion criteria
subjects with known intolerance of NO and iloprost or their constituents
acute decompensated heart failure within the 7 days before the invasive diagnostic procedure
clinically significant haemoptysis within the last 6 months
hemodynamic instability which would represent an unjustifiable risk during testing of pulmonary arterial vasoreagibility
arterial hypotension (as defined by age-specific values)
Anaemia
decompensated symptomatic policythemia; (details: 4.2.2. exclusion criteria)
Thrombocytopenia
secondary impairment of organic function:
impairment of renal function (GFR < 30 ml/min/1,73 m2 BSA)
impairment of hepatic function (ALT and/or AST > 3 x ULN and bilirubin ≥ 2 mg/dl)
other sources of pulmonary blood flow which prohibit measurement of the blood flow into the lungs and therefore of the pulmonary vascular resistance:
Glenn shunt, Anastomosis of superior vena cava to pulmonary artery
BT - Blalock-Taussig shunt, Subclavian to pulmonary artery shunt operation
significant number of MAPCAs; (details: 4.2.2. exclusion criteria)
Obstruction of pulmonary outflow tract
obstruction of pulmonary venous return
mitral valve dysfunction
Left heart diseases:
aortic or mitral valve disease (more severe than "mild")
restrictive or congestive cardiomyopathy
PCWP/LVEDP > 15 mmHg
symptomatic coronary artery disease
Significant valvular diseases other than tricuspid or pulmonary regurgitation (these are not exclusion criteria; details: 4.2.2. exclusion criteria).
PERICARDIAL CONSTRICTION
History of stroke, myocardial infarction or life-threatening arrhythmia within the 6 months before screening
Bronchopulmonary dysplasia (BPD) and other chronic lung diseases
History of significant pulmonary embolism
Other relevant diseases (e.g. HIV, diabetes mellitus requiring medical treatment)
Subjects with trisomy 21 (reproducibility of 6-MWT and CPX doubtful; communication as to side effects and subjective quality of life doubtful)
all contraindications against the study medication (see also "4.2.3 concomitant medication")
hypersensitivity against the active ingredients as well as supplementaries
patients who lost vision on one eye due to a non arteriitic anterior ischaemic neuropathy of the opticus (NAION).
Prohibited concomitant medication:
Any medication listed below which has not been discontinued at least 30 days prior to screening. Specific pulmonary vasodilators during cardiac catheterization are allowed.
Unspecified concomitant medication
Other significant medication (a.o. chronic intake of systemic immunosuppression as e.g. systemic glucocorticoids, cytostatic drugs, ciclosporin)
Instable medication (details: 4.2.5 prohibited concomitant medication):
begin of a new medication regimen within the last 30 days before screening
change in the dosage of existing medication within the last 7 days before cardiac catheterization
Existing anti-pulmonary hypertensive medication (in any form) with:
PDE-5 antagonists (e.g. sildenafil)
prostanoids (e.g. iloprost, prostacyclin, beraprost) In case the patient is stable and on Bosentan therapy at least for 6 months. Bosentan (Tracleer) is unprohibited as concomitant medication.
Other medication with vascular action:
Adrenergic alpha-Antagonists
L-arginin (acts through NO axis)
ritonavir, nicorandil (act through K+ channels)
Medication that is not compatible with sildenafil or interferes with the metabolism:
cytochrome P450-CYP2C9 and CYP3A4 inhibitors (e.g. erythromycin/ketoconazole/itraconazole/protease inhibitors)
any existing medication that, in the opinion of the investigator, may interfere with sildenafil treatment.